People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aviceda Therapeutics, Inc. | — | Biotechnology | Series D+ | $173.6M | $707.0M | 2021 |
Mohamed Genead at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mohamed Genead on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Guyer | 1 | 8 |
| Robert Kniaz | 1 | 5 |
| Patrick Johnson | 1 | 4 |
| Michael Tolentino | 1 | 3 |
| Erin Lavelle | 1 | 3 |
| Ross Darwin | 1 | 2 |
| Mariusz Gralewski | 1 | 2 |
| Dmytro Voloshyn | 1 | 2 |
| Kyrylo Bigay | 1 | 2 |
| Michael A. Tolentino | 1 | 1 |
| Christoph Adams | 1 | 1 |
| Tarek Hassan | 1 | 1 |
| Mohamed A. Genead | 1 | 1 |
| Derek Kunimoto | 1 | 1 |
| Jay Woods | 1 | 1 |
| Paul Vukelic | 1 | 1 |
| Derek A. Kunimoto | 1 | 1 |
| David Callanan | 1 | 1 |
| Nancy Thomason | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.